ストックスクリーナーアプリを入手
1.515
1.62%
-0.025
前日終値:
$1.54
開ける：
$1.55
24時間の取引高:
81,675
Relative Volume:
0.25
時価総額：
$100.22M
収益：
-
当期純損益:
$-30.04M
株価収益率:
-0.8964
EPS:
-1.69
ネットキャッシュフロー:
$-27.38M
1週間 パフォーマンス:
-0.98%
1か月 パフォーマンス:
-5.90%
6か月 パフォーマンス:
-15.13%
1年 パフォーマンス:
+18.36%
1日の値動き範囲:
$1.49
$1.57
1週間の範囲:
$1.455
$1.6201
52週間の値動き範囲:
$1.08
$3.79
Regulus Therapeutics Inc Stock (RGLS) Company Profile
名前
Regulus Therapeutics Inc
セクター
電話
858-202-6300
住所
4224 CAMPUS POINT COURT, SAN DIEGO, CA
RGLS を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
RGLS
Regulus Therapeutics Inc
|
1.51 | 100.22M | 0 | -30.04M | -27.38M | -1.58 |
|
VRTX
Vertex Pharmaceuticals Inc
|
401.29 | 103.35B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
704.36 | 77.35B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
624.08 | 37.04B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.54 | 30.14B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
111.56 | 26.97B | 3.30B | -501.07M | 1.03B | -2.1146 |
Regulus Therapeutics Inc Stock (RGLS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-08-02 | 開始されました | Oppenheimer | Outperform |
| 2024-03-18 | 開始されました | Leerink Partners | Outperform |
| 2018-03-28 | 開始されました | B. Riley FBR, Inc. | Neutral |
| 2018-01-05 | 開始されました | Leerink Partners | Outperform |
| 2017-06-13 | 繰り返されました | Chardan Capital Markets | Buy |
| 2017-03-06 | 繰り返されました | Wedbush | Outperform |
| 2017-01-30 | ダウングレード | Needham | Buy → Hold |
| 2017-01-30 | ダウングレード | Wells Fargo | Outperform → Market Perform |
| 2016-12-07 | 繰り返されました | Chardan Capital Markets | Buy |
| 2016-11-02 | 繰り返されました | Needham | Buy |
| 2016-07-25 | 繰り返されました | Chardan Capital Markets | Buy |
| 2016-06-28 | 繰り返されました | Chardan Capital Markets | Buy |
| 2016-06-28 | 繰り返されました | FBR Capital | Outperform |
| 2016-06-28 | 繰り返されました | Needham | Buy |
| 2016-06-07 | 繰り返されました | Chardan Capital Markets | Buy |
| 2016-04-13 | 開始されました | Chardan Capital Markets | Buy |
| 2015-12-04 | 開始されました | Wells Fargo | Outperform |
| 2015-06-09 | 開始されました | Guggenheim | Buy |
| 2015-04-21 | 再開されました | FBR Capital | Outperform |
| 2014-11-24 | 開始されました | Deutsche Bank | Buy |
| 2014-08-07 | 繰り返されました | FBR Capital | Outperform |
| 2013-08-14 | 繰り返されました | Needham | Buy |
すべてを表示
Regulus Therapeutics Inc (RGLS) 最新ニュース
Regulus Therapeutics Announces Completion of Enrollment in Secon - GuruFocus.com
Regulus Therapeutics Inc. (NASDAQ:RGLS) Receives $10.80 Average Target Price from Analysts - Defense World
Regulus Therapeutics Announces Participation at Two Healthcare Investment Conferences - The Eastern Progress Online
Institutional investors may overlook Regulus Therapeutics Inc.'s (NASDAQ:RGLS) recent US$12m market cap drop as long-term gains remain positive - Simply Wall St
Fmr LLC Reduces Position in Regulus Therapeutics Inc. (NASDAQ:RGLS) - MarketBeat
Regulus To Provide First Quarter 2017 Financial Results On May 4, 2017 - BioSpace
Regulus Therapeutics Inc. (NASDAQ:RGLS) Receives $10.80 Average Price Target from Brokerages - MarketBeat
The Manufacturers Life Insurance Company Purchases New Holdings in Regulus Therapeutics Inc. (NASDAQ:RGLS) - Defense World
Regulus Therapeutics Announces First Patient Dosed in Third Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) - StockTitan
Regulus Therapeutics Announces Participation at Upcoming Healthcare Investment Conferences - Longview News-Journal
Point72 Asset Management L.P. Takes $1.40 Million Position in Regulus Therapeutics Inc. (NASDAQ:RGLS) - MarketBeat
With 64% institutional ownership, Regulus Therapeutics Inc. (NASDAQ:RGLS) is a favorite amongst the big guns - Yahoo Finance
RA Capital Management L.P. Sells 5,483,166 Shares of Regulus Therapeutics Inc. (NASDAQ:RGLS) - MarketBeat
NEA Management Company LLC Buys Shares of 6,467,802 Regulus Therapeutics Inc. (NASDAQ:RGLS) - MarketBeat
Victory Capital Management Inc. Has $626,000 Holdings in Regulus Therapeutics Inc. (NASDAQ:RGLS) - Defense World
Regulus Therapeutics Announces Participation at Upcoming Healthc - GuruFocus.com
Regulus Therapeutics to Present at Evercore and Piper Sandler Healthcare Conferences - StockTitan
Brokerages Set Regulus Therapeutics Inc. (NASDAQ:RGLS) Price Target at $10.80 - MarketBeat
Regulus Therapeutics Reports Q3 2024 Financial Results - TipRanks
Regulus Therapeutics Reports Third Quarter 2024 Financial Results and Recent Updates - GuruFocus.com
Annovis Bio (NYSE:ANVS) versus Regulus Therapeutics (NASDAQ:RGLS) Head-To-Head Contrast - Defense World
RA Capital Management's Strategic Reduction in Regulus Therapeutics Holdings - GuruFocus.com
Biotechnology Value Fund L.P. Increases Stake in Regulus Therape - GuruFocus.com
What is HC Wainwright’s Estimate for RGLS FY2024 Earnings? - Defense World
FY2024 Earnings Forecast for RGLS Issued By HC Wainwright - MarketBeat
Creative Planning Makes New Investment in Regulus Therapeutics Inc. (NASDAQ:RGLS) - Defense World
Regulus Therapeutics (NASDAQ:RGLS) Receives Buy Rating from HC Wainwright - MarketBeat
Regulus: Q3 Earnings Snapshot - San Francisco Chronicle
Regulus Therapeutics (RGLS) Stock Price, News & Analysis - MarketBeat
Vanguard Group Inc's Strategic Acquisition in Regulus Therapeuti - GuruFocus.com
HC Wainwright Reiterates Buy Rating for Regulus Therapeutics (NASDAQ:RGLS) - MarketBeat
Regulus Therapeutics Inc. (NASDAQ:RGLS) Receives $10.80 Average PT from Analysts - MarketBeat
These 2 ‘Strong Buy’ Penny Stocks Could Rally Over 500%, Say Analysts - Yahoo Finance
Regulus Therapeutics secures exclusive license for kidney disease treatment - Investing.com India
Regulus Therapeutics secures exclusive license for kidney disease treatment By Investing.com - Investing.com South Africa
Regulus Therapeutics Inc. Enters into Patent & Technology License Agreement with the Board of Regents of the University of Texas System - Marketscreener.com
Financial Survey: Regulus Therapeutics (NASDAQ:RGLS) & Ironwood Pharmaceuticals (NASDAQ:IRWD) - Defense World
Renaissance Technologies LLC Has $211,000 Position in Regulus Therapeutics Inc. (NASDAQ:RGLS) - Defense World
HC Wainwright Reaffirms "Buy" Rating for Regulus Therapeutics (NASDAQ:RGLS) - MarketBeat
RGLSRegulus Therapeutics Inc. Latest Stock News & Market Updates - StockTitan
Regulus Therapeutics Announces Completion of Enrollment in Fourth Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD) - PR Newswire
Analysts Set Regulus Therapeutics Inc. (NASDAQ:RGLS) PT at $10.80 - MarketBeat
Company’s Banking Stock: Dissecting a -7.22% Quarterly Revenue Decline Amid Growth - The InvestChronicle
Regulus Therapeutics Inc [RGLS] stock for 7,280 USD was acquired by Collier Kathryn J - Knox Daily
Regulus Therapeutics Inc. (NASDAQ:RGLS) Shares Sold by CVI Holdings LLC - MarketBeat
Companies Like Regulus Therapeutics (NASDAQ:RGLS) Are In A Position To Invest In Growth - Simply Wall St
ProMIS Neurosciences (NASDAQ:PMN) versus Regulus Therapeutics (NASDAQ:RGLS) Critical Contrast - Defense World
Investing in Regulus Therapeutics Inc (RGLS) Is Getting More Attractive - Knox Daily
Victory Capital Management Inc. Has $645,000 Position in Regulus Therapeutics Inc. (NASDAQ:RGLS) - Defense World
Regulus Therapeutics Inc (RGLS) 財務データ
収益
当期純利益
現金流量
EPS
Regulus Therapeutics Inc (RGLS) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| CALSADA CRISPINA | Chief Financial Officer |
Jan 18 '24 |
Sale |
1.19 |
5,468 |
6,510 |
5,782 |
| Aker Christopher Ray | Sr. VP & General Counsel |
Jan 18 '24 |
Sale |
1.19 |
5,468 |
6,510 |
10,056 |
| Hagan Joseph P | Chief Executive Officer |
Jan 18 '24 |
Sale |
1.19 |
14,580 |
17,359 |
57,112 |
1.03%
0.20%
大文字化:
|
ボリューム (24 時間):